Boehringer Ingelheim sharpens retinal strategy, scooping up dry AMD drug from a Swiss team behind Novartis' Beovu
Boehringer Ingelheim has inked a second deal for retinal diseases in a year — and this time it’s specific about which ailment to target.
In a deal worth up to $490 million (CHF 474.5 million), the German pharma has locked in an antibody fragment-based drug for geographic atrophy from Zurich, Switzerland-based CDR-Life. Boehringer also gets a license to develop and commercialize other compounds against the specific target.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.